The Rogosin Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1983-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.rogosin.org/
Clinical Trials
24
Active:0
Completed:16
Trial Phases
4 Phases
Phase 1:1
Phase 2:3
Phase 4:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Not Applicable
7 (50.0%)Phase 2
3 (21.4%)Phase 4
3 (21.4%)Phase 1
1 (7.1%)Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
Not Applicable
Completed
- Conditions
- Dialysis HypotensionEnd Stage Renal DiseaseEnd Stage Renal Disease on DialysisDialysis Induced Hypertension
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 10
- Registration Number
- NCT05540457
- Locations
- 🇺🇸
The Rogosin Institute, New York, New York, United States
A Guided Meditation Program in Patients Undergoing Dialysis
Not Applicable
Completed
- Conditions
- End Stage Renal Disease
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 10
- Registration Number
- NCT04155216
- Locations
- 🇺🇸
The Rogosin Institute, New York, New York, United States
Anxiety and Symptom Burden in Hemodialysis Patients
Completed
- Conditions
- ESRDAnxiety
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 100
- Registration Number
- NCT04143100
- Locations
- 🇺🇸
The Rogosin Institute, New York, New York, United States
Procalcitonin and Brain Natriuretic Peptides in Patients With Chronic Kidney Disease.
Completed
- Conditions
- Kidney Failure, Chronic
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 79
- Registration Number
- NCT03698877
- Locations
- 🇺🇸
The Rogosin Institute, New York, New York, United States
Fructose-induced Hepatic De Novo Lipogenesis in Adolescents With Obesity
Not Applicable
Terminated
- Conditions
- Adolescent Obesity
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- The Rogosin Institute
- Target Recruit Count
- 12
- Registration Number
- NCT03567837
- Locations
- 🇺🇸
Weill Cornell Medicial College, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found